Jim Scibetta Named CEO of VectorY Therapeutics

VectorY Therapeutics has named Jim Scibetta as CEO, with founder Sander van Deventer transitioning to President of R&D. Scibetta, known for leading biotech innovations, will drive the clinical advancement of VTx-002, a promising vectorized antibody targeting TDP-43 for ALS, aiming to enter trials by 2025.

VectorY recently secured $138 million in Series A funding to develop its pipeline and has expanded to Boston. The company’s platform seeks to address neurodegenerative diseases by targeting underlying disease drivers, with VTx-002 positioned to preserve quality of life in ALS patients.